Research and Markets: Competitor Analysis - Hepatitis Vaccines 2011

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/1f418e/competitor_analysi) has announced the addition of the "Competitor Analysis - Hepatitis Vaccines" report to their offering.

The present Competitive Intelligence report about Hepatitis Vaccines provides a competitor evaluation in the field of marketed and novel prophylactic vaccines against hepatitis A, hepatitis B, hepatitis A and B, hepatitis C and hepatitis E viruses. Product description considers use of adjuvants and preservatives. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report includes a compilation of currently marketed vaccines and active projects in research and development for prophylaxis of hepatitis A, B, C and E. In addition, the report lists company-specific product portfolios and R&D pipelines of hepatitis vaccines on the market and in R&D. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

Key Topics Covered:

  • Single Hepatitis A Virus Vaccines
  • Dual Hepatitis A and B Virus Vaccines
  • Single Hepatitis B Virus Vaccines
  • Combination Vaccines including HAV Vaccines
  • Combination Vaccines including HBV Vaccines
  • Hepatitis C Virus Vaccines
  • Hepatitis E Virus Vaccines
  • Corporate Hepatitis Vaccine Product Portfolios and R&D Pipelines

For more information visit http://www.researchandmarkets.com/research/1f418e/competitor_analysi



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:

INDUSTRY KEYWORDS:   Health  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.